Cytovation AS is a privately held biotech company based in Bergen, Norway and specialising in the development of immunotherapy for solid tumours.
Who we are
Cytovation was founded in 2001 with strong ties to leading scientific research groups at Haukeland University Hospital and the University of Bergen. The company is currently developing CyPep-O1 for the treatment of multiple cancer indications.
The company’s founders are well-renowned experts in their fields and the authors of an extensive number of scientific publications.